Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
Authors
Keywords
-
Journal
JAMA Network Open
Volume 5, Issue 4, Pages e228879
Publisher
American Medical Association (AMA)
Online
2022-04-26
DOI
10.1001/jamanetworkopen.2022.8879
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database
- (2022) Ryan Y. S. Keh et al. BRAIN
- Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems
- (2022) Holly C. Groom et al. VACCINE
- Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
- (2022) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
- (2021) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
- (2021) Jessica R. MacNeil et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Surveillance for Adverse Events After COVID-19 mRNA Vaccination
- (2021) Nicola P. Klein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
- (2021) Hannah G. Rosenblum et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
- (2021) Kathleen Dooling et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021
- (2021) Emily Jane Woo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
- (2020) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Guillain-Barré Syndrome Incidence in a Large United States Cohort (20002009)
- (2012) Irene M. Shui et al. NEUROEPIDEMIOLOGY
- H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project
- (2011) Grace M. Lee et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis
- (2011) James J. Sejvar et al. NEUROEPIDEMIOLOGY
- The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety
- (2011) J. Baggs et al. PEDIATRICS
- Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data
- (2010) James J. Sejvar et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started